Effects of Enalapril Alone, and in Combination With Hydrochlorothiazide, on Renin-Angiotensin-Aldosterone, Renal Function, Salt and Water Excretion, and Body Fluid Composition

American Journal of Kidney Diseases

Volumn 6, Issue 4, 1985, Pages 222-232

  Bauer, John H ^a   Gaddy, Patricia ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; essential hypertension; glomerular filtration rate; primary

Indexed keywords

4 AMINOHIPPURIC ACID; ENALAPRIL; HYDROCHLOROTHIAZIDE; INULIN; NEW DRUG; PLACEBO; POTASSIUM CHLORIDE;

BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DRUG COMPARISON; DRUG EFFICACY; DRUG MIXTURE; DRUG THERAPY; ENDOCRINE SYSTEM; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; METHODOLOGY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THERAPY;

EID: 0022204098     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(85)80177-3     Document Type: Article

References (48)

1. Renal vascular response to interruption of the renin-angiotensin system in normal man
2. Increased glomerular filtration rate after converting enzyme inhibition in essential hypertension
3. Accentuated vascular and endocrine response to SQ 20,881 in hypertension
4. Effect of captopril on renal vascular tone in patients with essential hypertension
5. Clinical use of an orally acting converting enzyme inhibitor: Captopril
6. Sodium intake and renal responses to captopril in normal man and in essential hypertension
7. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man
8. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients
9. Interruption of the renin angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis
10. Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension
11. Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor
12. Hemodynamic and volume changes associated with captopril
13. Hemodynamic effects of captopril in essential and renovascular hypertension: correlations with plasma renin activity
14. Hypotensive and renal effects of captopril
15. Effect of captopril on renal function in patients with essential hypertension
16. Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation
17. Effect of N-[(S)l-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK421) an angiotensin converting enzyme in vitro and angiotensin II pressor response in vivo
18. Antihypertensive activity of N-[(S)-1-(ethoxy-carbonyl-3-phenylpropyl]-L-Ala-L-Pro (MK421), an orally active converting enzyme
19. A new class of angiotensin-converting enzyme inhibitors
20. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK421
21. Effects of the oral angiotensin-converting enzyme inhibitor in human hypertension
22. Antihypertensive therapy with MK421: Angiotensin II-renin relationship to evaluate efficacy of converting enzyme blockade
23. Effects of enalapril, a new converting enzyme inhibitor in hypertension
24. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine, and autonomic effects of MK421 (enalapril) and MK521
25. A comparative pilot study of enalapril, a new converting enzyme inhibitor and hydrochlorothiazide in essential hypertension
26. Temporal enhancement of renin-aldosterone blockade by enalapril, an angiotensin-converting enzyme inhibitor
27. Increased renal plasma flow in long-term enalapril treatment of hypertension
28. Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension
29. Effect of potassium chloride on plasma renin activity and plasma aldosterone during sodium restriction in normal man
30. Pressor responses to norepinephrine during captopril in renal prehypertensive rabbits
31. Body fluid composition in normal and hypertensive man
32. Renal function and hemodynamic studies in low- and normal-renin essential hypertension
33. Renin and renal function in benign essential hypertension: Evidence for a renal abnormality
34. Diurnal variation of plasma aldosterone control and renin activity in supine man
35. Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination
36. Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK421): a new angiotensin converting enzyme inhibitor
37. Role of angiotensin II in the physiologic regulation of glomerular filtration
38. Cytoplasmic contractile elements in glomerular cells
39. Contractile properties of the glomerular mesangium
40. Arachidonate metabolites and the control of glomerular filtration
41. Angiotensin II receptor regulation in isolated renal glomeruli
42. In vivo actions of angiotensin II on glomerular function
43. Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril
44. Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system and hypertension
45. Effect of chlorothiazide and sodium on vascular responsiveness to angiotensin II
46. Effects of propranolol therapy on renal function and body fluid composition
47. Effects of central alpha-adrenoceptor agonists and adrenergic-neuronal blocking agents on the kidney
48. 1-adrenoceptor antagonists and directly acting vasodilators on the kidney